๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

โœ Scribed by Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Jager, E.; Heintges, T.; Stoll, C.; Giessen, C.; Modest, D. P.; Neumann, J.; Jung, A.; Kirchner, T.; Scheithauer, W.; Heinemann, V.

Book ID
118060323
Publisher
Oxford University Press
Year
2012
Tongue
English
Weight
225 KB
Volume
23
Category
Article
ISSN
0923-7534

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
โœ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa ๐Ÿ“‚ Article ๐Ÿ“… 2014 ๐Ÿ› Lancet Publishing Group ๐ŸŒ English โš– 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow